Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Director/PDMR Shareholding

12 Aug 2013 07:00

RNS Number : 4202L
ReNeuron Group plc
12 August 2013
 

 

DTR3

 

NOTIFICATION OF TRANSACTIONS OF DIRECTORS/ PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND CONNECTED PERSONS

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

ReNeuron Group plc

2.

State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.2R; or (ii) a disclosure made in accordance with LR 9.8.6R(1); or (iii) in accordance with section 793 of the Companies Act 2006

 

(i)

 

3.

Name of person discharging managerial responsibilities/director

 

Dr. Paul Harper

4.

State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3

and identify the connected person

 

Director named in 3.

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest 1

 

Interest of person named in 3

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

Ordinary Shares

 

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

Person named in 3

 

8.

State the nature of the transaction

 

Placing of Ordinary Shares

9.

Number of shares, debentures or financial instruments relating to shares acquired

 

Acquisition of 200,000 Ordinary Shares

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

 

0.011%

 

11.

Number of shares, debentures or financial instruments relating to shares disposed

 

 

 

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

 

 

13.

Price per share or value of transaction

 

2.5 pence per Ordinary Share

 

14.

Date and place of transaction

 

9 August 2013

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

Dr. Paul Harper is interested in a total of 451,709 Ordinary Shares in the Company representing approximately 0.025% of issued Ordinary Shares.

 

16.

Date issuer informed of transaction

 

9 August 2013

 

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

 

17.

Date of grant

 

 

18.

Period during which or date on which it can be exercised

 

19.

Total amount paid (if any) for grant of the option

20.

Description of shares or debentures involved (class and number)

 

21.

Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

 

22.

Total number of shares or debentures over which options held following notification

23.

Any additional information

 

See table of options held by Dr. Paul Harper below:

 

 

 

Number of options

Exercise Price

End of Exercise Period

98,781

12.65p

August 2015

98,688

5.07p

August 2016

258,098

12.2p

August 2017

226,682

4.85p

August 2019

277,797

4.43p

August 2020

417,274

4.31p

August 2021

500,000

3.3pp

August 2022

1,877,300

24.

Name of contact and telephone number for queries

 

Pat Huggins, Reneuron Group Plc

+44 (0)1483 302560

 

 

Name of authorised official of issuer responsible for making notification:

 

Patrick Huggins, Head of Finance and Company Secretary

 

Date of notification: 9 August 2013

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFEETIIAIIV
Date   Source Headline
5th Apr 20197:00 amRNSReNeuron to present at UK investor conference
4th Apr 20197:00 amRNSClinical update and conference presentation
28th Mar 20192:05 pmRNSSecond Price Monitoring Extn
28th Mar 20192:00 pmRNSPrice Monitoring Extension
18th Mar 201912:00 pmRNSAlliance for Regenerative Medicine presentation
18th Mar 20197:00 amRNSRetinal clinical trial progresses to next stage
12th Mar 20192:30 pmRNSNotification of Major Holdings
5th Mar 201912:56 pmRNSNotification of Major Holdings
5th Mar 20197:00 amRNSNotification of Major Holdings
5th Mar 20197:00 amRNSNotification of Major Holdings
28th Feb 20197:00 amRNSBlock Listing Review and Total Voting Rights
20th Feb 20197:00 amRNSPositive preliminary data in US retinal trial
31st Jan 20197:00 amRNSNew exosome production scale-up data presented
24th Jan 20197:00 amRNSFirst patient treated in US stroke trial
4th Jan 20197:00 amRNSReNeuron signs exosome collaboration
14th Dec 20187:00 amRNSInterim Results
20th Nov 20182:00 pmRNSNotification of Interim Results
18th Oct 20187:00 amRNSReNeuron's lead cell line shows further potential
28th Sep 20182:16 pmRNSDirector/PDMR Interest in Shares and Share Options
27th Sep 20183:02 pmRNSDirectors Share Purchases
19th Sep 20184:40 pmRNSSecond Price Monitoring Extn
19th Sep 20184:35 pmRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSBusiness development update
12th Sep 201811:40 amRNSResult of AGM
12th Sep 20187:00 amRNSAGM Trading Update
31st Aug 20187:00 amRNSBlock Listing Review and TVR
31st Jul 20183:25 pmRNSPosting of Annual Report & Notice of AGM
17th Jul 20187:00 amRNSNotification of Major Holdings
16th Jul 20183:39 pmRNSNotification of Major Holdings
16th Jul 20187:00 amRNSNotification of Major Holdings
13th Jul 201811:50 amRNSNotification of Major Holdings
12th Jul 20187:00 amRNSPreliminary Results
11th Jul 20187:00 amRNSSigns retinal stem cell exclusivity agreement
4th Jul 20182:15 pmRNSNotification of Preliminary Results
17th May 20187:00 amRNSCapital Markets Event
4th May 20187:00 amRNSExosome data presented at ISCT conference
30th Apr 20187:00 amRNSCapital Markets Event and Webcast
19th Apr 20187:00 amRNSWins grant for retinal cell therapy development
10th Apr 20181:00 pmRNSAppointment of US-based Chief Medical Officer
26th Mar 20187:00 amRNSProduct Development Update
1st Mar 20187:00 amRNSBlock Listing Review and TVR
16th Feb 20187:00 amRNSBlock Listing Application
13th Feb 201810:00 amRNSPositive pre-clinical data in nerve injury
26th Jan 20187:00 amRNSPhase II stroke data presented at AHA conference
23rd Jan 201811:06 amRNSApproval of Share Capital Reorganisation
11th Jan 20187:00 amRNSFurther re Share Capital Reorganisation
5th Jan 20187:00 amRNSProposed Share Capital Reorganisation
14th Dec 20177:00 amRNSInterim results
14th Dec 20177:00 amRNSStroke clinical trial regulatory approval in US
8th Dec 20177:00 amRNSReNeuron opens US office

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.